Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Agenus Inc.
  • Applied Genetic Technologies Corp.
  • Ariad Pharmaceuticals Inc.
  • Can-Fite BioPharma Ltd.
  • Capricor Therapeutics
  • Celldex Therapeutics Inc.
  • Celsion Corp.
  • Cempra Inc.
  • Cesca Therapeutics Inc.
  • CTI BioPharma
  • Fate Therapeutics Inc.
  • Galectin Therapeutics Inc.
  • GenVec Inc.
  • Keryx Biopharmaceuticals Inc.
  • La Jolla Pharmaceutical Co.
  • Lion Biotechnologies
  • MEI Pharma Inc.
  • Neuralstem Inc.
  • NewLink Genetics Corp.
  • Novartis AG
  • OncoSec Medical Inc.
  • Oncothyreon Inc.
  • Paratek Pharmaceuticals Inc.
  • Peregrine Pharmaceuticals Inc.
  • Radius Health Inc.
  • RXi Pharmaceuticals Corp.
  • Spectrum Pharmaceuticals Inc.
  • Sunesis Pharmaceuticals Inc.
  • Synta Pharmaceuticals Corp.
  • TG Therapeutics Inc.
  • Threshold Pharmaceuticals Inc.
  • Verastem Inc.

Reni Benjamin

H.C. Wainwright & Co.

Image: Reni Benjamin

Dr. Reni Benjamin is a managing director and equity research analyst at H.C. Wainwright & Co. His expertise and coverage focuses on companies in the oncology and stem cell sectors. Benjamin has been ranked among the top analysts for recommendation performance and earnings accuracy by StarMine, has been cited in a variety of sources including The Wall Street Journal, Bloomberg Businessweek, Financial Times and Smart Money, and has made appearances on Bloomberg television/radio and CNBC. He authored a chapter in “The Delivery of Regenerative Medicines and Their Impact on Healthcare,” has presented at various regional and international conferences, and has been published in peer-reviewed journals. He currently serves on the UAB School of Health Professions' Deans Advisory Board. Prior to joining H.C. Wainwright, Benjamin was a managing director and senior biotechnology analyst at both Burrill Securities and Rodman & Renshaw. He was also an associate analyst at Needham and Company. Benjamin earned his doctorate from the University of Alabama at Birmingham in biochemistry and molecular genetics by discovering and characterizing a novel gene implicated in germ cell development. He earned a bachelor's degree in biology from Allegheny College.




Recent Interviews

Watchlist Analysts Forecast Continued Blue Sky for Biotech Industry (1/29/15) For the last two years the biotech sector has experienced market-beating gains, even taking into account the industry-wide hiccup in early 2014. Can this trend continue? The five analysts who selected names for The Life Sciences Report's 2015 Small-Cap Biotech Watchlist spend their days considering this question; it comes into play with every recommendation they make. The topic came up in various contexts during the Watchlist panel at the 2015 Biotech Showcase: Here are four factors investors should consider as they move into 2015.

The Small-Cap Biotech Watchlist 2015 Unwrapped: Who Are These Guys? And Why Are They Here? (1/27/15) At the Biotech Showcase 2015 in San Francisco, five biotech analysts examined the burgeoning small-cap life sciences marketplace and found every reason to believe its good health would continue into 2015 and beyond. The experts also sent investors who attended the panel discussion of The Life Sciences Report's 2015 Small-Cap Biotech Watchlist home with a bundle of robust investment opportunities, including a few new names. Read on to see which companies made the list, and why.

2015 Small-Cap Biotech Watchlist Announced (12/18/14) In its third year, The Life Sciences Report's 2015 Small-Cap Biotech Watchlist currently includes 12 drug development companies selected by leading analysts in the sector. With catalysts on the horizon and pipelines that encompass a variety of indications and innovative platforms, these biotechs are primed to return multiples on investment.

Recent Quotes

"Data from CANF's psoriasis study are a near-term value driver." (3/19/15) Can-Fite BioPharma Ltd. - Reni Benjamin, H.C. Wainwright & Co. More >

"CUR showed a subset of ALS patients may benefit from its cell therapy." (3/17/15) Neuralstem Inc. - Reni Benjamin, H.C. Wainwright & Co. More >

"CANF's CF602 generated a 118% improvement in a physiological index of ED relative to placebo." (1/28/15) Can-Fite BioPharma Ltd. - Reni Benjamin, H.C. Wainwright & Co. More >

"CANF's oral psoriasis candidate has shown some very, very promising data." (1/27/15) Can-Fite BioPharma Ltd. - The Life Sciences Report Interview with Reni Benjamin More >

"RXII announced a global licensing agreement for rights to Samcyprone." (12/22/14) RXi Pharmaceuticals Corp. - Reni Benjamin, H.C. Wainwright & Co. More >

"RXII is an undervalued player with significant upside long term." (11/18/14) RXi Pharmaceuticals Corp. - Reni Benjamin, H.C. Wainwright & Co. More >

"CANF represents an undervalued player with significant upside for long-term investors." (11/8/14) Can-Fite BioPharma Ltd. - Reni Benjamin, H.C. Wainwright & Co. More >

"CUR's forward progress of the NSI-556 trial for SCI is welcome news." (10/13/14) Neuralstem Inc. - Reni Benjamin, H.C. Wainwright & Co. More >

more comments

"CUR's NSI-566 could be a treatment capable of producing long-lasting and durable responses." (9/23/14) Neuralstem Inc. - Reni Benjamin, H.C. Wainwright & Co. More >

"RXII's study data showed statistically significant improvement." (9/11/14) RXi Pharmaceuticals Corp. - Reni Benjamin, H.C. Wainwright & Co. More >

"We are initiating coverage on CUR." (9/8/14) Neuralstem Inc. - Reni Benjamin, H.C. Wainwright & Co. More >

"RXII could report preliminary data over the next four to six months." (8/15/14) RXi Pharmaceuticals Corp. - Reni Benjamin, H.C. Wainwright & Co. More >

"KOOL's expanded collaboration with Fortis is excellent news." (8/5/14) Cesca Therapeutics Inc. - Reni Benjamin, H.C. Wainwright & Co. More >

"KOOL's expanded collaboration with Fortis is excellent news." (8/5/14) Cesca Therapeutics Inc. - Reni Benjamin, H.C. Wainwright & Co. More >

"RXII represents an undervalued player in the RNA interference space." (7/31/14) RXi Pharmaceuticals Corp. - Reni Benjamin, H.C. Wainwright & Co. More >

"We feel RXII has largely been ignored by investors, but has potential." (7/10/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Reni Benjamin More >

"KOOL is an undervalued player with significant long-term upside." (7/8/14) Cesca Therapeutics Inc. - Reni Benjamin, H.C. Wainwright & Co. More >

"We are initiating coverage on KOOL with a Buy rating." (6/26/14) Cesca Therapeutics Inc. - Reni Benjamin, H.C. Wainwright & Co. More >

"RXII is an undervalued player with significant upside long term." (5/16/14) RXi Pharmaceuticals Corp. - Reni Benjamin, H.C. Wainwright & Co. More >

"We are initiating coverage on RXII with a Buy rating." (5/5/14) RXi Pharmaceuticals Corp. - Reni Benjamin, H.C. Wainwright & Co. More >

"KOOL has the potential to make a significant mark in the regenerative medicine space." (2/11/14) Cesca Therapeutics Inc. - The Life Sciences Report Interview with Reni Benjamin More >

"Investors should definitely take a look at KOOL." (12/12/13) Cesca Therapeutics Inc. - The Life Science Report Interview with Reni Benjamin More >

"MSB has a 1,700-patient phase 3 study in progress, evaluating Revascor in congestive heart failure—clearly a big market." (12/12/13) Mesoblast Ltd. - The Life Sciences Report Interview with Reni Benjamin More >

"CUR is making significant strides in the regenerative medicine space." (12/12/13) Neuralstem Inc. - The Life Sciences Report Interview with Reni Benjamin More >

"RXII is one of the key players in the RNAi space that I think show significant promise." (12/12/13) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Reni Benjamin More >

"INO is developing and advancing DNA vaccines with a twist." (12/11/13) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Reni Benjamin More >

fewer comments


Due to permission requirements, not all quotes are shown.